The aim is to explore how treatment with ruxolitinib affects the neutrophil-to-lymphocyte ratio in patients with polycythemia vera in relation to JAK2 variant allele frequency.
Analyzed neutrophil-to-lymphocyte ratios before and after treatment with ruxolitinib.
Measured JAK2 variant allele frequencies in participants.
Investigated correlations between neutrophil-to-lymphocyte ratio changes and JAK2 frequencies.
A significant change in the neutrophil-to-lymphocyte ratio was observed following ruxolitinib treatment.
Changes in the ratio correlated with variances in JAK2 allele frequency.